Results 121 to 130 of about 25,222 (249)
, 1993 liver cirrhosis induces important changes in the time-course of naltrexone with higher bioavailability of naltrexone and slower conversion to 6-beta ...
FERRARI, Anna +6 more
core
Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan +6 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 9, September 2026.ABSTRACT Background and Aims Long COVID, also known as post‐acute sequelae of SARS‐CoV‐2 infection (PASC), is a multisystem condition characterized by persistent symptoms that continue beyond the acute phase of infection. Growing evidence indicates that sustained immune dysregulation involving cytokine‐mediated inflammation, complement activation ...
Emmanuel Ifeanyi Obeagu
wiley +1 more source
RATIONALE FOR THE SELECTION OF AUXILIARY COMPONENTS FOR THE NALTREXONE HYDROCHLORIDE NASAL SPRAY
Разработка и регистрация лекарственных средств, 2019 The work is devoted to the development of nasal spray containing naltrexone hydrochloride. Naltrexone in doses of 3-5 mg/day acts on the opioid growth factor receptor (OGFr) and toll-like receptor 4 that makes it promising for use in the complex therapy ...
Y. M. Domnina +3 more
doaj
Physiological ReportsThe aim of this study is to determine if extended‐release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone
Robert L. Joyner +6 more
doaj +1 more source
The Evolution of Medications for Obesity Management
JGH Open, Volume 10, Issue 9, September 2026.ABSTRACT This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns.
Jaskirath Gill, Priya Sumithran
wiley +1 more source
Hell's Itch: A Self‐Case Report
JEADV Clinical Practice, Volume 5, Issue 3, Page 982-985, September 2026.ABSTRACT Hell's itch is a severely distressing dermatological condition characterized by the onset of incessant itching and intolerable pain 2–3 days post‐sunburn. It is underdiagnosed and underreported, and no definitive management framework has yet been developed.
Kai Peter Moors, Willem I. Visser
wiley +1 more source
The Six Pillars of Lifestyle Medicine in MASLD: An Evidence‐Based Guide
Liver International Communications, Volume 7, Issue 3, September 2026.ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is projected to affect more than 40% of adults by 2050. Although pharmacologic therapies are emerging, lifestyle modification remains the foundation of management.
Jigyasa Sharma, Kathleen Viveiros
wiley +1 more source
Obesity, Volume 34, Issue S2, Page 119-131, September 2026.ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu +5 more
wiley +1 more source
Il naltrexone nel trattamento del prurito
, 2005 Naltrexone is a cyclopropyl derivative of oxymorphone which behaves as a competitive antagonist of opioid receptors. Naltrexone is usually used in weaning opioid-dependent patients.
S. Veraldi, R. Caputo
core